In those studies, recombinant SAA1 media concentrations of 10 μg/mL were used to treat C2C12 myotubes, this corresponds to reported SAA1 concentrations in plasma of tumor‐bearing mice (Buczek et al., 2018) and non‐small‐cell lung cancer patients (Kim et al., 2015). The gene discussed is SAA1; the disease is neoplasm.